PSTX - Poseida Therapeutics Inc
IEX Last Trade
2.85
0.090 3.158%
Share volume: 194,313
Last Updated: Fri 30 Aug 2024 09:59:55 PM CEST
Research and Development in Biotechnology (except Nanobiotechnology):
0.21%
PREVIOUS CLOSE
CHG
CHG%
$2.76
0.09
3.26%
View ratios
| Fiscal Date | 2022-06-30 | 2022-09-30 | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 | 2024-03-31 | |
|---|---|---|---|---|---|---|---|---|---|
| Fiscal Quarter | Q2 2022 | Q3 2022 | Q4 2022 | Q1 2023 | Q2 2023 | Q3 2023 | Q4 2023 | Q1 2024 | |
| Report Date | 2022-08-11 | 2022-11-10 | 2023-03-09 | 2023-05-09 | 2023-08-08 | 2023-11-09 | 2024-03-07 | 2024-05-14 | |
| Assets | |||||||||
| Total Assets | 205.455 M | 380.481 M | 351.837 M | 313.621 M | 281.215 M | 302.252 M | 273.885 M | 262.580 M | |
| Current Assets | 148.119 M | 325.129 M | 298.563 M | 260.696 M | 230.195 M | 252.664 M | 226.475 M | 216.732 M | |
| Inventories | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Other Current Assets | 5.330 M | 7.677 M | 6.982 M | 5.058 M | 3.683 M | 5.155 M | 5.263 M | 6.059 M | |
| Short Term Investments | 5.330 M | 7.677 M | 6.982 M | 5.058 M | 3.683 M | 5.155 M | 5.263 M | 6.059 M | |
| Total Receivables | 232.000 K | 38.467 M | 9.088 M | 8.437 M | 11.906 M | 8.672 M | 9.010 M | 12.027 M | |
| Current Cash | 142.557 M | 278.985 M | 282.493 M | 247.201 M | 214.606 M | 238.837 M | 212.202 M | 198.646 M | |
| Total Non-current Assets | 57.336 M | 55.352 M | 53.274 M | 52.925 M | 51.020 M | 49.588 M | 47.410 M | 45.848 M | |
| Property Plant Equipment | 22.756 M | 21.748 M | 21.586 M | 22.114 M | 21.011 M | 20.382 M | 19.055 M | 18.364 M | |
| Other Assets | 29.032 M | 28.056 M | 26.140 M | 25.263 M | 24.461 M | 23.658 M | 22.807 M | 21.936 M | |
| Intangible Assets | 1.320 M | 1.320 M | 1.320 M | 1.320 M | 1.320 M | 1.320 M | 1.320 M | 1.320 M | |
| Goodwill | 4.228 M | 4.228 M | 4.228 M | 4.228 M | 4.228 M | 4.228 M | 4.228 M | 4.228 M | |
| Liabilities and shareholders’ equity | |||||||||
| Total Liabilities and shareholders’ equity | 205.455 M | 380.481 M | 351.837 M | 313.621 M | 281.215 M | 302.252 M | 273.885 M | 262.580 M | |
| Total liabilities | 139.655 M | 164.168 M | 164.242 M | 156.056 M | 145.914 M | 178.592 M | 170.184 M | 177.986 M | |
| Total current liabilities | 40.093 M | 48.968 M | 53.885 M | 48.690 M | 49.888 M | 76.973 M | 71.318 M | 84.763 M | |
| Accounts Payable | 3.661 M | 3.426 M | 2.228 M | 3.200 M | 2.097 M | 2.542 M | 3.267 M | 2.704 M | |
| Other liabilities | 14.639 M | 31.249 M | 27.416 M | 25.298 M | 14.808 M | 21.265 M | 19.394 M | 14.657 M | |
| Current long term debt | 6.686 M | 6.737 M | 5.866 M | 5.820 M | 5.863 M | 5.906 M | 5.951 M | 5.995 M | |
| Long term debt | 84.868 M | 83.896 M | 82.886 M | 82.068 M | 81.218 M | 80.354 M | 79.472 M | 78.566 M | |
| Other liabilities | 14.639 M | 31.249 M | 27.416 M | 25.298 M | 14.808 M | 21.265 M | 19.394 M | 14.657 M | |
| Minority interest | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Total Shareholder equity | 65.800 M | 216.313 M | 187.595 M | 157.565 M | 135.301 M | 123.660 M | 103.701 M | 84.594 M | |
| Common stock | 62.713 M | 76.287 M | 86.258 M | 86.265 M | 86.795 M | 91.898 M | 95.782 M | 96.020 M | |
| Retained earnings | -507.952 M | -437.543 M | -470.861 M | -509.708 M | -537.164 M | -568.942 M | -594.291 M | -618.565 M |